236 related articles for article (PubMed ID: 16625858)
1. Potential indications for somatostatin analogs in Cushing's syndrome.
Arnaldi G; Polenta B; Cardinaletti M; Boscaro M
J Endocrinol Invest; 2005; 28(11 Suppl International):106-10. PubMed ID: 16625858
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
3. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.
Hofland LJ; van der Hoek J; Feelders R; van Aken MO; van Koetsveld PM; Waaijers M; Sprij-Mooij D; Bruns C; Weckbecker G; de Herder WW; Beckers A; Lamberts SW
Eur J Endocrinol; 2005 Apr; 152(4):645-54. PubMed ID: 15817922
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin and somatostatin receptors in Cushing's disease.
Hofland LJ
Mol Cell Endocrinol; 2008 May; 286(1-2):199-205. PubMed ID: 18221833
[TBL] [Abstract][Full Text] [Related]
5. The role of somatostatin analogs in Cushing's disease.
van der Hoek J; Lamberts SW; Hofland LJ
Pituitary; 2004; 7(4):257-64. PubMed ID: 16132202
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide for the treatment of Cushing's disease.
Arnaldi G; Boscaro M
Expert Opin Investig Drugs; 2010 Jul; 19(7):889-98. PubMed ID: 20533892
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
9. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
10. Drugs in the medical treatment of Cushing's syndrome.
Schteingart DE
Expert Opin Emerg Drugs; 2009 Dec; 14(4):661-71. PubMed ID: 19939210
[TBL] [Abstract][Full Text] [Related]
11. Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.
Castillo V; Theodoropoulou M; Stalla J; Gallelli MF; Cabrera-Blatter MF; Haedo MR; Labeur M; Schmid HA; Stalla GK; Arzt E
Neuroendocrinology; 2011; 94(2):124-36. PubMed ID: 21525729
[TBL] [Abstract][Full Text] [Related]
12. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.
Batista DL; Zhang X; Gejman R; Ansell PJ; Zhou Y; Johnson SA; Swearingen B; Hedley-Whyte ET; Stratakis CA; Klibanski A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4482-8. PubMed ID: 16940446
[TBL] [Abstract][Full Text] [Related]
13. Is there a role for somatostatin and its analogs in Cushing's syndrome?
de Herder WW; Lamberts SW
Metabolism; 1996 Aug; 45(8 Suppl 1):83-5. PubMed ID: 8769391
[TBL] [Abstract][Full Text] [Related]
14. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
15. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
Losa M; Mortini P; Giovanelli M
Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362
[TBL] [Abstract][Full Text] [Related]
16. Is there a therapeutic role for octreotide in patients with ectopic Cushing's syndrome?
Uwaifo GI; Koch CA; Hirshberg B; Chen CC; Hartzband P; Nieman LK; Pacak K
J Endocrinol Invest; 2003 Aug; 26(8):710-7. PubMed ID: 14669823
[TBL] [Abstract][Full Text] [Related]
17. [Cushing's syndrome. II. New forms of treatment].
van Aken MO; Feelders RA; van der Lely AJ; Romijn JA; Lamberts SW; de Herder WW
Ned Tijdschr Geneeskd; 2006 Oct; 150(43):2365-9. PubMed ID: 17100127
[TBL] [Abstract][Full Text] [Related]
18. Ectopic Cushing's syndrome: Paradoxical effect of somatostatin analogs.
Biagetti B; Simó-Servat O; Ortiz-Z A; Iglesias C; Mesa J
Endocrinol Diabetes Nutr; 2017 May; 64(5):276-278. PubMed ID: 29056252
[No Abstract] [Full Text] [Related]
19. Octreotide exerts different effects in vivo and in vitro in Cushing's disease.
Stalla GK; Brockmeier SJ; Renner U; Newton C; Buchfelder M; Stalla J; Müller OA
Eur J Endocrinol; 1994 Feb; 130(2):125-31. PubMed ID: 8130885
[TBL] [Abstract][Full Text] [Related]
20. Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome.
Willenberg HS; Stratakis CA; Marx C; Ehrhart-Bornstein M; Chrousos GP; Bornstein SR
N Engl J Med; 1998 Jul; 339(1):27-31. PubMed ID: 9647876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
